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László G. Puskás 2,3 and Gábor K. Tóth 1*
1Department of Medical Chemistry, University of Szeged, Szeged, Hungary, 2 Avidin Ltd., Szeged, Hungary, 3Department of
Genetics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary
A general strategy for the synthesis of N-peptide-6-amino-D-luciferin conjugates has
been developed. The applicability of the strategy was demonstrated with the preparation
of a known substrate, N-Z-Asp-Glu-Val-Asp-6-amino-D-luciferin (N-Z-DEVD-aLuc).
N-Z-DEVD-aLuc was obtained via a hybrid liquid/solid phase synthesis method,
in which the appropriately protected C-terminal amino acid was coupled to
6-amino-2-cyanobenzothiazole and the resulting conjugate was reacted with D-cysteine
in order to get the protected amino acid-6-amino-D-luciferin conjugate, which was then
attached to resin. The resulting loaded resin was used for the solid-phase synthesis
of the desired N-peptide-6-amino-D-luciferin conjugate without difficulties, which was
then attested with NMR spectroscopy and LC-MS, and successfully tested in a
bioluminescent system.
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INTRODUCTION
In the recent years, numerous in vivo and in vitro analytical methods have been developed based on
fluorescence and bioluminescence, including immunoassays, gene expression assays, bioimaging,
investigation of infectious diseases etc., (Ioka et al., 2016; Kaskova et al., 2016); plate based,
high-throughput viability assays addressing the detection of protease activity is in the focus of
intensive research (Kepp et al., 2011). Protease activity can be detected with both fluorescent and
bioluminescent detection systems, but with the latter the detection threshold is orders of magnitude
lower than that of the fluorescent technique (O’Brien et al., 2005; Hickson et al., 2010; Gilbert and
Boutros, 2016).
In the bioluminescent methods, diverse sets of luciferases and their substrates, luciferins have
been applied in different cellular and animal models (Ioka et al., 2016; Kaskova et al., 2016).
Aminoluciferin (aLuc) is a luciferin with its 6-position hydroxyl group substituted with an amino
group. This modification allows aLuc to form amide bond with a peptide, while retaining the
transport and bioluminescent properties of luciferin, resulting in a good substrate for different
important proteases, which can be used for the determination of the enzymatic activity mentioned
above (White et al., 1966).
N-linked peptide-6-amino-D-luciferins can be substrates for different proteases, including
metalloproteases, chymotrypsin-like, trypsin-like, and caspase-like proteases (O’Brien et al., 2008)
They can be used for measuring protease enzyme activity in the following way: the protease enzyme
to be measured recognizes the peptide part of the conjugate with the suitable peptide sequence,
then cleaves the amide bond between the peptide and the aLuc, thus aLuc is released, which, in the
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presence of luciferase enzyme, emits light (Figure 1). The activity
of the given protease enzyme can be determined from the amount
of emitted light, as the emitted light is directly proportional to the
activity of the enzyme (Leippe et al., 2011).
In the ongoing research the authors have developed and
optimized amore efficientmethod for the synthesis ofN-peptide-
6-amino-D-luciferin conjugates in general, with a simpler set-
up under milder conditions. N-Z-DEVD-aLuc was chosen to
demonstrate the applicability of the strategy because it is a
commercially available but very expensive compound, which
is used to measure the activity of caspase-3, and consequently
the efficiency of apoptosis-inducing drugs (Talanian et al., 1997;
McStay et al., 2008).
Literary Overview
The logical method for the synthesis of N-peptide-6-amino-
D-luciferin conjugates would start with the synthesis of the
key molecule, 6-amino-2-cyanobenzothiazole. So far very few
methods have been published for this step (Takakura et al., 2011;
Gryshuk et al., 2013; McCutcheon et al., 2015; Hauser et al.,
2016; Hsu et al., 2016; see Supplementary Table 1). The key
steps of all these methods are the nitration, the cyanidation and
the NO2 reduction; the methods differ in the starting material,
the reagents, the solvents and the order of the transformations.
Having examined these methods, it can be seen that they have
disadvantages:
a. A less optimal starting material may require an extra
transformation during the synthesis (see Supplementary
Table 2).
b. Certain synthesis routes require too much reagents, some
of which are expensive (see Comments in Supplementary
Table 1).
c. The use of an ill-chosen solvent leads to low yield during the
chlorine-cyanide exchange (see Supplementary Table 3).
Abbreviations: AcN, acetonitrile; anh, anhydrous; APCI, atmospheric
pressure chemical ionization; API, atmospheric pressure ionization;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate;
COMU, 1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate; cps, counts per seconds; DCC,
dicyclohexylcarbodiimide; DCM, dichloromethane; Deoxo-Fluor Reagent,
bis(2-methoxyethyl)aminosulfur trifluoride; DIPEA, N,N-diisopropylethylamine;
DMAA, N,N-dimethylacetamide; DMAP, 4-dimethylaminopyridine; DMEM,
Dulbecco’s modified eagle medium; DMEM-F12, Dulbecco’s modified eagle
medium nutrient mixture F-12; DMF, N,N-dimethylformamide; DMSO, dimethyl
sulfoxide; DTT, 1,4-dithiothreitol; EDTA, disodium ethylenediaminetetraacetate
dehydrate; EtOAc, ethyl acetate; FACS, fluorescence activated cell sorter;
FCS, fetal calf serum; Fmoc, 9-fluorenylmethoxycarbonyl Fmoc; HATU, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid; HMPA, hexamethylphosphoric acid triamide; HOBt 1-hydroxybenzotriazole;
i.p., intraperitoneally; MeOH, methanol; mp, melting point; PBS, phosphate-
buffered saline; RP-HPLC, reversed-phase high-performance liquid
chromatography; SEM, standard error of the mean; SPPS, solid phase
peptide synthesis; TCFH, chloro-N,N,N′ ,N′-tetramethylformamidinium
hexafluorophosphate; TFA, trifluoroacetic acid; TFFH, fluoro-N,N,N′,N′-
tetramethylformamidinium hexafluorophosphate; THF, tetrahydrofuran;
TLC, thin layer chromatography; Z, benzyloxycarbonyl; Z-VAD-fmk,
benzyloxycarbonyl-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone.
d. A less optimal order of the transformations results in low
yield (by transformation and, consequently, overall). With the
optimal order, however, a transformation on one functional
group does not result in a side reaction on the other functional
group (see Supplementary Table 4).
Ideally, in the next step the amino group of the 6-amino-2-
cyanobenzothiazole is blocked with a protecting group. However,
the low nucleophilicity of the amino group makes its protection
problematic, resulting in very low yield. Therefore, a different
synthesis route is needed. One method has been published
(Gryshuk et al., 2011; see Supplementary Table 5). Instead
of a protecting group, the amino group of the 6-amino-2-
cyanobenzothiazole is blocked with the protected C-terminal
amino acid of the target sequence, and then the protecting group
is removed from the C-terminal amino acid. In the following
step, the remaining part of the target sequence is added and the
side chain protecting groups of the peptide portion are removed;
finally cysteine is added. However, the route has disadvantages:
a. The mixed anhydride method for the acylation is not optimal,
because it is not economical.
b. Due to the basic conditions (pH 8) during the cysteine
addition, there is a risk of racemization.
c. The resulting materials are purified twice during the route,
which is unnecessary.
d. Yields were not determined, therefore it is difficult to evaluate
the synthesis route.
MATERIALS AND METHODS
Materials
2-chlorobenzothiazole, HATU, TCFH, DCC, and D-
Cys·HCl·H2O were obtained from AK Scientific Inc. (Union
City, CA, USA). Z-Asp(OtBu)-OH and COMU were sourced
from Bachem (Bubendorf, Switzerland). Fmoc-amino acids were
purchased from Orpegen (Heidelberg, Germany) and Bachem
(Bubendorf, Switzerland); Wang resin from Rapp Polymere
GmbH (Tuebingen, Germany), TFFH from Fluorochem Ltd.,
(Hadfield, UK). The HOBt was sourced from Carbosynth
Ltd (Compton, UK), trifluoroacetic acid gradient grade from
VWR International (Radnor, PA, USA). The following reagents
were purchased from Sigma-Aldrich (St. Louis, MO, USA):
Deoxo-Fluor Reagent, PBS, trypsin, HEPES, CHAPS, DTT,
EDTA, DMEM-F12, penicillin, streptomycin, 0.1% saponin.
Alexa Fluor R© 488 was bought from Thermo Fisher Scientific
(Waltham, MA, USA). N-Z-DEVD-aLuc, C150 (Nagy et al.,
2015; Hackler et al., 2016), and Ac-915 (Nagy et al., 2013) were
synthesized by Avidin Ltd., (Szeged, Hungary).
Thin layer chromatography was performed on silica gel plates
60 F254 from Merck (Darmstadt, Germany). Melting points
were determined using Büchi (Flawil, Switzerland) melting point
apparatus Model B-545. pH values were measured with a Hanna
HI 8424 pH meter. Cellulose extraction thimbles were purchased
from Whatman (Maidstone, UK). Analytical reversed-phase
high-performance liquid chromatography was performed on an
Agilent 1,200 series separations module with diode array and
multiple wavelength detector (Waldbronn, Germany), with a
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FIGURE 1 | The operation of the bioluminescent system.
Luna C18(2) 100 Å column (10µm, 250× 4.6mm) Phenomenex,
(Torrance, CA, USA). The experiments were carried out at room
temperature with a flow rate maintained at 1.2ml min−1 at
220 nm wavelength (mobile phases solvent A: 0.1% TFA in Milli-
Q water and solvent B: 0.1% TFA in AcN) using gradient elution.
Separation was achieved on a Shimadzu (Kyoto, Japan) semi-
preparative system with a Jupiter C18 300 Å column (10µm,
250× 21.20mm), also from Phenomenex (mobile phases solvent
A: 0.1% TFA in Milli-Q water and solvent B: 0.1% TFA in AcN)
using gradient elution. Mass spectrometry data for the 2-chloro-
6-nitrobenzothiazole (1) were collected on a Finnigan MAT TSQ
7,000 (Waltham, MA, USA) instrument, operating with APCI
in negative ion mode, data for materials 2, 3, 8 were collected
on Waters (Milford, MA, USA) SQ Detector with API mass
spectrometer in positive ion mode; data for compounds 4 and
5 were recorded with Waters Q-Tof Premier Mass Spectrometer.
1H NMR and 13C NMR spectra were recorded using a Bruker
DR × 500 spectrometer at 600 MHz and 150 MHz, respectively
in [D6]DMSO. Chemical shifts were reported on the δ scale and
J values were given in Hz.
Caspase-3 and the assay buffer were used from the Caspase-3
inhibitor drug screening kit from BioVision (Milpitas, CA, USA).
Black plastic microtiter plates were purchased from Tomtec
(Budapest, Hungary), Z-VAD-fmk from Calbiochem (San
Diego, CA, USA) and Merck Millipore, (Billerica, MA, USA),
luminescence detection reagent from Promega (Madison, WI,
USA). 9661S caspase-3 antibody from Cell Signaling Technology
(Leiden, TheNetherlands). Luminescence was recorded as counts
per seconds by a plate reader Perkin ElmerWallac VICTOR 1420
(Waltham, MA, USA). A549 non-small cell lung carcinoma cells
were purchased from the ATCC (Manassas, VA, USA) and U87-
Luc glioblastoma cell line from Perkin Elmer (Waltham, MA,
USA). Tissue culture dishes (60mm dishes. 96-well plates) were
purchased from Corning (Corning, NY, USA). DMEM and FBS
were purchased fromGibco BRL (Gaithersburg, MD, USA). Male
SCID mice (6 weeks old, 22–24 g body weight) were supplied by
Innovo Ltd. (Budapest, Hungary). We used IVIS 100 imaging
instrument from Xenogen, (Alameda, CA, USA). CellQuestTM
software was bought from Becton Dickinson (Franklin Lakes, NJ,
USA), GraphPad Prism R© 5 from GraphPad Software (La Jolla,
CA, USA).
The mouse studies were performed according to the
Institutional and National Animal Experimentation and
Ethics Guidelines in possession of an ethical clearance
(XXIX./3610/2012), provided by the Head of Foodchain-
safety and Animal Health of the Csongrad County Government
Office. Document number: CSI/01/126/2013. Valid until 8th of
January 2018.
Methods
Preparation of 2-chloro-6-nitrobenzothiazole (1)
Four hundred and thirty eight milliliter cc H2SO4 was cooled
to 10◦C in a 2-liter triple-neck round-bottomed flask. 100 g
(0.59mol) 2-chlorobenzothiazole was dripped to the sulfuric
acid over a period of 2 h, meanwhile the reaction mixture
was stirred vigorously and the temperature was held under
15◦C. Sixty-Six grams (0.66mol) powdered KNO3 was added
to the reaction mixture in small quantities in 45min, the
temperature was still kept under 15◦C. Then the reactionmixture
was allowed to warm up to room temperature, and stirring
was continued at room temperature for 2 h. It was poured
into 4 liters of ice and water. Yellow precipitation formed,
which was filtered and washed until the pH of the filtrate
became neutral. The crystalline compound was dried at room
temperature, followed by its recrystallization from ethyl acetate
in order to get rid of 2-chloro-5-nitrobenzothiazole as the single
side product. The resulting material was a pale yellow crystal,
its weight was 104.90 g (0.49mol), yield 83%, mp 191-192◦C
(EtOAc), (lit. mp 190–191◦C, Katz, 1951). 1H-NMR (CDCl3,
500 MHz) δ 8.77 (s, 1H), 8.41 (d, J = 9.0Hz, 1H), 8.10
(d, J = 9.0Hz, 1H) (Supplementary Figure 1). The spectral
data matched that in the literature (Shinde et al., 2006) m/z
(TSQ): 213.93 [M-H]− (Supplementary Figure 2), RP-HPLC:
70–100% B in 15min + 100% B in 5min, tR = 7.899min
(Supplementary Figure 3), TLC: n-hexane/dioxane = 2:1;
Rf: 0.42.
Preparation of 6-amino-2-chlorobenzothiazole (2)
Twenty-five gram (0.12mol) 2-chloro-6-nitrobenzothiazole (1)
packed in a paper cup and 500ml ethyl acetate, 30 g NH4Cl
(0.56mol), 200ml water, and 20 g reduced Fe powder in a
1-liter round-bottomed flask was put in a Soxhlet apparatus
and heated under reflux for 8 h while continuously stirring the
mixture. This way, the continuous dissolution of the starting
material, which has low solubility in ethyl acetate, was ensured,
allowing for unmonitored and unmanaged operation while we
could efficiently recycle a small amount of ethyl acetate to
dissolve a larger amount of 2-chloro-6nitro-benzothiazole, thus
making the procedure more economical. In order to get rid
of the remaining water/NH4Cl/Fe-powder as lower part, the
upper part ethyl acetate layer was decanted, and this process
was repeated twice with 100ml ethyl acetate, respectively.
Decantation was employed instead of using a separatory funnel
because the lower aqueous phase too viscous. We had no
iron waste as in our method no chemical transformation of
the iron occurred, the iron was 100% recyclable: the iron
powder was filtered off, and then washed on a Büchner
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funnel with distilled water. The combined organic phase was
dried over anhydrous Na2SO4, filtered and evaporated on
rotary evaporator. The resulting material was a yellow crystal,
its weight was 18.90 g (0.10mol), yield 88%, mp 154–156◦C
(EtOAc) (lit.155–157◦C, Katz, 1951). 1H NMR ([D6]DMSO,
600 MHz) δ (d, J = 8.4Hz, 1H), 7.04 (d, J = 2.4Hz,
1H), 6.78 (dd, J1 = 1.8Hz, J2 = 8.4Hz, 1H), 5.53 (bs,
2H) (Supplementary Figure 4), 13C NMR ([D6]DMSO, 150
MHz) δ 148.24, 145.51, 142.00, 137.86, 123.13, 115.51, 104.18
(Supplementary Figure 5). The spectral data matched that in
the literature (Reddy et al., 2010). m/z (ESI): 185.0 [M + H]+
(Supplementary Figure 6), RP-HPLC: 5–80% B in 25min +
3min up to 100% B + 100% B in 5min, tR = 11.527min
(Supplementary Figure 7), TLC: n-hexane/dioxane = 2:1;
Rf: 0.76.
Preparation of 6-amino-2-cyanobenzothiazole (3)
In order to get a suspension, 6.1 g (93.0 mmol) KCN was
sonicated in 400ml DMAA for 3 × 15min. The suspension was
heated in an oil-bath at 98–100◦C under argon atmosphere and
then 6.86 g (37.15 mmol) 6-amino-2-chlorobenzothiazole (2),
dissolved in 20ml DMAA, was dripped to this reaction mixture
over a period of 50min. This resulting mixture was heated
in an oil-bath at 110◦C and stirred continuously under argon
atmosphere for 12 h. After 12 h stirring there was still starting
material in the mixture. An increased conversion from the
starting ratio of 2.5:1 for KCN/6-amino-2-chlorobenzothiazole
(2) to the ratio of 3.4:1 was achieved by adding 2.20 g (33.80
mmol) of KCN. This was followed by 5 h stirring under
the conditions described above, and after that procedure the
remaining amount of 6-amino-2-chlorobenzothiazole (2) was
insignificant. The reaction mixture was poured on a mixture
of 200 g ice, 400ml 1M KH2PO4 and 300ml ether. The
organic phase was separated from the aqueous phase. The
latter was extracted with 2 × 250ml ether, then with 2
× 200ml ethyl acetate. The combined organic phases were
washed with 2 × 300ml water and 1 × 300ml brine,
dried over anhydrous Na2SO4 and concentrated on rotary
evaporator. The resulting material was a pale brown solid,
its weight was 6.4 g (crude). The material was recrystallized
from acetone, and the impurities were removed by adding
activated charcoal to the solution. The weight of the desired
purified material was 5.09 g (29.10 mmol), yield 78%, mp 218–
219◦C (EtOAc) (lit. mp 216–218◦C, White et al., 1966). 1H
NMR ([D6]DMSO, 600 MHz) δ (d, J = 9.0Hz, 1H), 7.22
(d, J = 1.8Hz, 1H), 7.01 (dd, J1 = 1.8Hz, J2 = 9.0Hz,
1H), 4.40 (bs, 2H) (Supplementary Figure 8), 13C NMR
(150 MHz, ([D6]DMSO) δ 150.06, 144.10, 138.75, 128.86,
125.62, 118.19, 114.71, 103.54 (Supplementary Figure 9). The
spectral data matched that in the literature (McCutcheon
et al., 2015). m/z (ESI) 176.0 [M + H]+ (Supplementary
Figure 10), RP-HPLC: 5–80% B in 25 + 3min up to
100% B + 5 in 100% B, tR = 16.692min (Supplementary
Figure 11), TLC: n-hexane/dioxane= 2:1; Rf: 0.48. The remaining
KCN was reacted with KH2PO4 in order to get non-toxic
KOCN.
Preparation of
Fmoc-Asp(OtBu)-6-amino-2-cyanobenzothiazole (4)
6.30 g (15.30 mmol, 1.5 equiv) Fmoc-Asp(OtBu)-OH, which was
previously dried in a vacuum desiccator, and 4.30 g (15.30 mmol,
1.5 equiv) TCFH were solved in 35ml dry DCM. The mixture
was stirred for 60min at room temperature. First 3.06ml (18.36
mmol, 1.8 equiv) DIPEA, then 1.79 g (10.20 mmol, 1 equiv) 6-
amino-2-cyanobenzothiazole, which was previously dried in a
vacuum desiccator, were added. Further 200ml dry DCM was
added to get complete dissolution of the materials. After stirring
the reaction mixture overnight at room temperature, it was
transferred into a separatory funnel and washed with water (2
× 30ml), with saturated NaHCO3-solution (2 × 30ml), then
with water again (2 × 30ml), and finally with brine (2 × 30ml).
It was dried over anhydrous Na2SO4, finally concentrated on
rotary evaporator. The resulting crude material was a yellowish-
brown powder, its weight was 6.17 g. RP-HPLC analysis showed
a yield of 73%. m/z (TOF) 569.2070 [M + H]+ (Supplementary
Figure 12), RP-HPLC (for the purified compound): 50–100% B
in 25min, tR = 10.591min (Supplementary Figure 13), TLC:
ethanol (EtOH)/toluene 50:7.5; Rf: 0.58.
Synthesis of Fmoc-Asp(OtBu)-6-amino-D-luciferin (5)
2.96 g (5.20 mmol) Fmoc-Asp(OtBu-)-6-amino-2-
cyanobenzothiazole was dissolved in the mixture of 35ml
MeOH and 20ml THF. 1.37 g (7.80 mmol) D-cysteine·HCl·H2O,
dissolved in 10ml distilled water, was added to the mixture
at room temperature under argon atmosphere, while stirring
continuously under pH control (starting pH: 1.67). After 20min
stirring at room temperature 16ml 5% (m/m) NaHCO3 was
added dropwise over a period of 1 h to the mixture in order
to release cysteine from its salt while continuously checking
pH. Reaching pH 2.5, a fine, yellow solid material, Fmoc-
Asp(OtBu)-6-amino-D-luciferin free carboxylic acid, started to
precipitate. At pH 6.1, this material started to dissolve, and at
pH 7.36, it dissolved completely. Here the Fmoc-Asp(OtBu)-6-
amino-D-luciferin formed Na-salt, which dissolved under the
basic conditions. After an additional 20min stirring at room
temperature the organic solvent was removed under reduced
pressure. Water and methanol forms an azeotrope, and the
two solvents were therefore removed together through the
distillation. Due to the decrease in the concentration of the water,
from the remaining aqueous solution a yellow solid material,
Fmoc-Asp(OtBu)-6-amino-D-luciferin Na-salt, precipitated.
This, however, was just an irrelevant event during the process, as
our goal was the removal of the methanol. The aforementioned
precipitate is water soluble, so then it was dissolved again
in 20ml water and extracted with 1 × 15ml ethyl acetate in
order to get rid of possible impurities. Having dropped this
solution on a mixture of ice and glacial acetic acid (adjusted to
pH 3), a fine yellow precipitate formed, Fmoc-Asp(OtBu)-6-
amino-D-luciferin free carboxylic acid. It was allowed to settle
for 10min, filtered and washed with 3 × 10ml water, then
air-dried to constant weight, which was 2.83 g (4.20 mmol),
yield 81%. m/z (TOF) 673.1882 [M + H]+ (Supplementary
Figure 14), RP-HPLC: 50–100% B in 25min, tR = 21.046min
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(Supplementary Figure 15), TLC: toluene/EtOH 50:30 saturated
with water, Rf: 0.58.
Attachment of Fmoc-Asp(OtBu)-6-amino-D-luciferin
to Solid Support (6)
Solid phase peptide synthesis was performed manually by using
a solid phase vessel attached to a rotating apparatus. 0.127 g
(0.10 mmol, 1 equiv) p-alkoxybenzyl alcohol resin was allowed
to swell in anh DCM for 20min. After the removal of the
DCM, 0.202 g (0.30 mmol, 3 equiv) Fmoc-Asp(OtBu)-amino-
D-luciferin, 0.062 g (0.30 mmol, 3 equiv) DCC, 0.041 g (0.30
mmol, 3 equiv) HOBt, and 0.037 g (0.10 mmol, 1 equiv) DMAP,
dissolved in 10ml anh DCM, was added to the resin. The
coupling reaction was shaken for 3 h at room temperature. After
the removal of the coupling mixture, the resin was rinsed with
DCM (3 × 10ml), MeOH (1 × 10ml) and then with DCM (3
× 10ml) again. The coupling reaction was repeated with the
soln of 0.067 g (0.10 mmol, 1 equiv) Fmoc-Asp(OtBu)-amino-D-
luciferin, 0.062 g (0.30 mmol, 3 equiv) DCC, 0.041 g (0.30 mmol,
3 equiv) HOBt and 0.037 g (0.10 mmol, 1 equiv) DMAP in 5ml
anh DCM at room temperature for 2 h. The resin was drained
and rinsed with DCM (3 × 10ml), MeOH (1 × 10ml), DCM (3
× 10ml), then dried to constant weight.
Determination of load
5mg of dried loaded resin was treated with a mixture of
TFA/water (500 µl, with the ratio of 95:5) for 1 h at room
temperature. This was followed by the addition of 500 µl water
to the cocktail, which was then filtered off. 10 µl from the
filtrate was injected to analytical RP-HPLC and the area of the
Fmoc-Asp-6-amino-D-luciferin on the resulted chromatogram
was compared with the area of 10 ul Fmoc-Asp-6-amino-D-
luciferin stock solution with the concentration of 1 mg/ml. The
resulting load was 47.8%.
Preparation of N-Z-DEVD-aLuc (8)
Fmoc deprotection
Fmoc deprotection was carried out by suspending the resin in
20% (v/v) piperidine/DMF (5ml) and agitating the vessel at room
temperature for 2× 10min. The suspension was then filtered and
the resin was washed with DMF (3 × 5ml), MeOH (3 × 5ml),
DMF (3× 5ml).
SPPS peptide coupling (7)
Fmoc-Val-OH (3 equiv), DCC (3 equiv), and HOBt (3 equiv)
dissolved in DMF were added to the previously swollen
and Fmoc-deprotected loaded resin (1 equiv). The resulting
suspension was agitated at room temperature for 2 h and the resin
was then rinsed with DMF (3 × 5ml), MeOH (3 × 5ml), DMF
(3× 5ml).
The same procedure was carried out with Fmoc-Glu(OtBu)-
OH (3 equiv) and Z-Asp(OtBu)-OH, (3 equiv). The presence or
absence of the Nα-free amino group was monitored using the
Kaiser test.
Cleavage of peptide from the resin
The peptide-resin (7) was treated with a solution of TFA/water
(95:5 v/v) for 2 h at room temperature. After the removal of the
cleaving mixture, the resin was rinsed with AcN (3 × 10ml),
MeOH (1× 10ml) and with AcN (3× 10ml) again. The resulting
material is a yellow liquid, which was lyophilized afterwards. RP-
HPLC for the crude compound: 5–80% B in 25min + 3min up
to 100% B + 5min in 100% B, tR = 18.483min (Supplementary
Figure 16).
Purification of crude peptide
26mg crude peptide was dissolved in acetic acid/water (1.5ml,
with the ratio of 1:1), then filtered, using a 0.45µm nylon
filter. Gradient elution was used, 0–60% eluent B in 60min at
a 3ml min−1 flow rate with detection at 220 nm. Pure fractions
were collected and lyophilized to give a pale yellow material,
the weight of which was 11.4mg (0.013 mmol). 1H NMR (600
MHz, [D6]DMSO) δ 10.26 (bs, 1H), 8.61 (s, 1H), 8.42 (d,
J = 7.2Hz, 1H), 8.08 (d, J = 9.0Hz, 2H), 7.81 (bs, 1H), 7.64 (dd,
J1 = 9.0Hz, J2 = 29.4Hz, 2H), 7.34 (s, 5H), 5.42 (t, J = 8.4Hz,
1H), 5.02 (s, 2H), 4.69 (d, J = 7.2Hz, 1H), 4.34 (dd, J1 = 5.4Hz,
J2 = 29.4Hz, 2H), 4.12 (bs, 1H), 3.77 (t, J = 10.8Hz, 1H), 3.68
(dd, J1 = 8.4Hz, J2 = 11.4Hz, 1H), 2.77 (bs, 1H), 2.61–2.68
(m, 2H), 2.25–2.46 (m, 3H), 1.76–1.99 (m, 2H), 0.83–0.86 (m,
7H) (Supplementary Figure 17 part 1,2,3), 13C NMR (150 MHz,
[D6]DMSO) δ 174.54, 172.00, 171.61, 171.38, 170.24, 159.62,
156.32, 149.14, 138.66, 137.31, 136.71, 128.83, 128.28, 128.19,
124.65, 120.28, 112.04, 78.64, 66.01, 58.21, 52.53, 51.86, 51.24,
36.77, 36.31, 35.23, 30.98, 30.52, 27.59, 19.53 (Supplementary
Figure 18 part 1,2), m/z (ESI) 872.3 [M + H]+ (Figure 2), RP-
HPLC: 5–80% B in 25min + 3min up to 100% B + 5min in
100% B, tR = 18.555min (Figure 3).
N-Z-DEVD-aLuc Biochemical Assay
Caspase-3 and the assay buffer were used from the caspase-3
inhibitor drug screening kit. Caspase-3 was used in ten-fold serial
dilution starting from 227 mU to 22.7 µU/reaction. N-Z-DEVD-
aLuc substrate was applied in 100µM to 1µM in 25 µl final
reaction volume in a black plastic microtiter plate. The effect of
the pan-caspase inhibitor Z-VAD-fmk was tested in equimolar
ratio of N-Z-DEVD-aLuc at 10µM with 2.27 mU/reaction
caspase-3. After 45min incubation at 37◦C we added 25 µl
luminescence detection reagent to each well. Luminescence was
recorded as cps by a plate reader within 5min. Blank wells
contained each component except caspase-3. Presented values are
blank-subtracted.
Cell Lines and Culture
A549 cells and U87-Luc glioblastoma cells were maintained
in DMEM-F12 and DMEM cell culture media, respectively.
Both type of medium were supplemented with 10% (v/v)
heat-inactivated FBS, 100 units/ml penicillin and 100 mg/ml
streptomycin at 37◦C in a humidified atmosphere containing
5% CO2.
N-Z-DEVD-aLuc Cellular Assay
A549 non-small cell lung carcinoma cells (2 × 106) were plated
in 60mm dishes in DMEM-F12 media. After cell attachment
(24 h), the cells were treated with curcumin analog C150 (5µM to
1.25µM) in order to induce apoptosis in 5ml final volume (Nagy
et al., 2015). After 24 h incubation supernatant was harvested and
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FIGURE 2 | Mass spectrum (ESI) of the purified N-Z-DEVD-aLuc (8) 872.3 = [M+H]+.
FIGURE 3 | RP-HPLC profile of the purified N-Z-DEVD-aLuc (8), 5–80% B in 25 + 3min up to 100% B + 5min in 100% B, tR = 18.555min.
kept on ice. Cells were washed with PBS and trypsinized (5min,
37◦C). Supernatant, washing PBS and media blocked trypsin
were mixed and centrifuged down (5min, 4◦C, 1,800 g). Lysis
buffer was diluted with distilled water (five times concentrated
lysis buffer: 250mM HEPES, pH 7.4, 25mM CHAPS, 25mM
DTT, and 50 µl 1x concentration lysis buffer was added to the
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pellet, resuspended and kept on ice for 15min. Samples were
centrifuged down for 10min (4◦C, 11,000 g). Supernatant of the
lysate was harvested and kept on ice for analysis. N-Z-DEVD-
aLuc was dissolved in DMSO at 10mM and used in 10µM in
the assay. Assay buffer was diluted in distilled water (ten times
concentrated assay buffer: 200mM HEPES, pH 7.4, 1% (V/V)
CHAPS, 50mM DTT, 20mM EDTA, 95 µl 1x concentration
assay buffer containing 10µM N-Z-DEVD-aLuc was measured
in 96-well tissue culture plate and 5 µl lysate was assayed
in triplicates to detect luminescence proportional to caspase-3
activity. Blank contained 5 µl assay buffer instead of the lysate.
After 4 h reaction 50µl reactionmixture wasmeasured into black
plastic microtiter plate and 50 µl luminescent detection reagent
was added. Luminescence was recorded as cps by a plate reader
within 5min. Presented values are blank-subtracted.
In Vivo Animal Model
Male SCID mice (6 weeks old, 22–24 g body weight) were housed
in sterile cages at Avidin Ltd. The mice were fed autoclaved food
and sterile water ad libitum. For inoculation, the U87-Luc cells
were trypsinized, washed and resuspended in sterile PBS. The
mice were injected subcutaneously with this suspension (3× 106
cells in 0.2ml), in the dorsal region, unilaterally. All operative
procedures and animal care conformed strictly to the Hungarian
Council on Animal Care guidelines. (Approval provided by Head
of Foodchain-safety and Animal Health of the Csongrad County
Government Office. Document number: CSI/01/126/2013; valid
until 8th of January 2018.) 18 days after inoculation the mice
were treated with Ac-915, a lipid droplet binding thalidomide
analog inducing oxidative stress and apoptosis in glioblastoma
cells (Nagy et al., 2013). Ac-915 was dissolved in DMSO:solutol
3:1 mixture, then diluted in PBS four times and injected i.p. at a
20 mg/kg dose except negative control mice which were injected
by PBS only. Six hours after drug administration, to monitor
apoptosis induction, the mice were injected i.p., with 50 mg/kg
N-Z-DEVD-aLuc in PBS, followed by anesthetization in 2–3%
isoflurane atmosphere. 30min after the injection of the substrate,
the mice were imaged using a charge coupled device camera in
the IVIS 100 imaging instrument.
Statistics
Statistical significance was calculated with unpaired t-test (two-
tailed, homoscedastic) between untreated and one treated
sample. Each point represents the average of 3 wells ± SEM.
Values are blank-subtracted (blank = no caspase). ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001.
RESULTS AND DISCUSSION
The desired peptide-luciferin conjugate (N-Z-DEVD-aLuc) was
reached in an 8-step route (Figure 4, Supplementary Table 6):
nitration → reduction → chlorine-cyanide exchange →
attachment of the C-terminal amino acid of the target sequence
→ cysteine addition → attachment to resin → solid-phase
peptide synthesis→ cleavage from resin.
As starting material, cheap, commercially available 2-
chlorobenzothiazole was used, which was first nitrated with a
mixture of potassium nitrate and concentrated sulphuric acid,
keeping the temperature at 0◦C (Katz, 1951). The structure
of the resulting 2-chloro-6-nitrobenzothiazole (1) was attested
by 1H-NMR spectrum. The next step was the reduction of
the nitro-group. First the mixture of ethanol/glacial acetic
acid/iron powder was used (Katz, 1951). Although the reaction
was successful, the resulting by-product (iron(III) acetate)
was difficult to dispose of, so this method was dismissed.
When trying the reduction with tin(II) chloride/glacial acetic
FIGURE 4 | The synthetic route to N-Z-DEVD-aLuc. Reagents and conditions: (a) ccH2SO4/KNO3, 0–15
◦C, 5h (b) EtOAc, NH4Cl, H2O, Fe powder, reflux, 8h (c)
KCN, DMAA, 110◦C, 12h (d) Fmoc-Asp(OtBu)-OH, TCFH, dry DCM, DIPEA, overnight, rt (e) D-Cys Hcl H2O, THF, MeOH, H2O, 5 m/m% NaHCO3, 2h, rt (f)
p-alkoxybenzyl alcohol resin, dry DCM, DCC, HOBt, DMAP, 5 h 30min (g) Fmoc -/Z-protected amino acid. DCC. HOBt, DMF, 2 h, rt; 20% (v/v) piperidine for Fmoc
deprotection, 20min, rt (h) TFA/H2O 95:5 (v/v), 2 h, rt.
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acid/concentrated hydrogen chloride, large amounts of by-
product formed, in which the chlorine was split off or substituted
with a hydroxyl group, so this method also had to be dismissed.
The third possibility was the application of sodium pyrosulphite,
which also turned out to be unsatisfactory due to the reduction
giving a very low yield. Using zinc/hydrogen chloride led to the
same results as with tin(II) chloride.
Finally, applying ethyl acetate, water, ammonium chloride,
and iron powder system solved the problem and the reduction
was successful with a good yield. Using a Soxhlet extractor
turned out to be a solvent-sparing, thus environmentally-friendly
method and processing the obtained product was also simple: the
solution had to be decanted in order to get rid of the iron powder
and then extracted.
The next step—the chlorine/nitrile exchange in the 6-amino-
2-chlorobenzothiazole (2)—is the key in the production of the
desired conjugates. Six different methods had to be tried, the
common features of which were the polar aprotic non-aqueous
solvent, the high temperature and the long reaction time (a)
anh DMSO/KCN, 160◦C, 10 h; (b) anh DMSO/KCN/KI, 160◦C,
10 h; (c) anh DMSO/18-crown-6/KCN, 120◦C, 8 h; (d) anh
DMF/KCN, 140◦C, 12 h; (e) anh HMPA/KCN, 140◦C, 10 h; (f)
f) anh DMAA/KCN/KI, 120◦C, 8 h).
The first five methods had to be dismissed due to the low
yield (15–20%). When trying DMAA, however, it turned out that
KCN is dissolved best in this solvent, resulting in relatively high
yield (75–80%) This means that the success of the chlorine/nitrile
exchange depends on the rate of KCN dissolution.
An Fmoc-protected amino acid (Fmoc-Asp(OtBu)-OH) was
coupled to the 6-amino-2-cyanobenzothiazole (3). As, due to
the deactivated amino group, the amide bond could not be
formed with the usual coupling reagent, DCC, a much more
activating coupling agent was necessary. Different agents were
tested in different quantities: COMU (El-Faham and Albericio,
2010; Takakura et al., 2011; Chantell et al., 2012), HATU (El-
Faham et al., 2010), Deoxo-Fluor Reagent (El-Faham et al., 2010),
TFFH (Kangani et al., 2006), and TCFH (Carpino et al., 1996), all
with a ratio of 1:1.5 and 1:3. The best yield (97%) was obtained
with 1.5 equivalents of TCFH (Table 1). Other than the quantity
of the different coupling reagents, all other conditions (solvent,
reaction time, temperature etc.) were kept the same. Although
TABLE 1 | Coupling agents and yields.
Coupling agent Quantity Yield (%)
COMU 1.5 equiv 0
COMU 3.0 equiv 0
HATU 1.5 equiv 7
HATU 3.0 equiv 8
Deoxo-fluor reagent 1.5 equiv 48
Deoxo-fluor reagent 3.0 equiv 38
TFFH 1.5 equiv 59
TFFH 3.0 equiv 51
TCFH 1.5 equiv 97
TCFH 3.0 equiv 72
it was not checked with chiral chromatography at this point,
it became obvious following the achiral chromatography after
the cysteine addition that there was no racemization, because if
there had been, during either this or the previous step, we would
have seen diastereomers. As the achiral chromatography after the
cysteine addition was indispensable anyway, we could save the
rather complicated chiral chromatography one step earlier.
During the addition of D-cysteine (Tulla-Puche et al.,
2008) to the resulting conjugate (Fmoc-Asp(OtBu)-6-amino-2-
cyanobenzothiazole, (4), the amino acid-heterocycle conjugate
was dissolved in THF andMeOH, then D-cysteine hydrochloride
monohydrate was added. The resulting compound was dissolved
in water, and then the cysteine was released from its salt with
NaHCO3. During the reaction (about 25min) the pH of the
solution was kept between 7.3-7.4 by the addition of NaHCO3
aqueous solution, monitoring the process with a pH-meter
and the addition was carried out under argon atmosphere. By
this way, the desired amino acid-6-amino-D-luciferin conjugate,
Fmoc-Asp(OtBu)-6-amino-D-luciferin (5) was obtained.
During the next step this conjugate was attached to resin (6).
Two types of resins were tested: 2-chlorotrityl chloride and p-
alkoxybenzyl alcohol (Wang resin). Loading was checked in both
cases: with 2-chlorotrityl chloride resin it was 30%, while with
Wang resin it was 50%, so we decided to use the latter.
Classical solid phase peptide synthesis was carried out: the
peptide chain was built with Fmoc strategy. However, the N-
terminal amino acid was always Z-protected, as this protecting
group gives higher biological stability to the peptide. The
obtained peptide-aLuc conjugate was removed from the resin
with the mixture of TFA/water (95:5 v/v); finally, the resulting
material was purified by preparative HPLC.
The material—N-Z-DEVD-aLuc (7)—was successfully tested
in a bioluminescent system. It has been published that both
caspase-3 and caspase-7 digest DEVD sequence, but caspase-3
has six time higher DEVD digestion activity (Talanian et al., 1997;
McStay et al., 2008) so we tested N-Z-DEVD-aLuc by the activity
of caspase-3 in vitro (Figure 5) and caspase-3 in vivo (Figure 6).
The purity of the peptide is demonstrated in Supplementary
Figure 19. The biological relevance of our N-Z-DEVD-aLuc
substrate was confirmed in a biochemical reaction using a serial
dilution of recombinant caspase-3 from 227 mU/reaction to
22.7 µU/reaction. In order to verify that our N-Z-DEVD-aLuc
is a real substrate for caspase-3, not only the enzyme but also
the N-Z-DEVD-aLuc substrate was titrated in a concentration
range from 100 to 1µM. The recorded luminescence was
linearly proportional with the growing enzyme activity and
increased amount of the N-Z-DEVD-aLuc substrate showing
maximum cps at 227 mU caspase-3 and 100µM N-Z-DEVD-
aLuc (Figure 5A, Supplementary Figure 20) Moreover, the
luminescence signal was completely abolished by the application
of equimolar pan-caspase inhibitor Z-VAD-fmk in the reaction
of 2.27 mU caspase-3 and 10µM N-Z-DEVD-aLuc (Ion et al.,
2006; Figure 5B). We further verified the applicability of our N-
Z-DEVD-aLuc substrate to detect cellular apoptotic cell death
caused by a drug candidate molecule. The curcumin analog C150
induces caspase-3 activation (Szebeni et al., 2017; Supplementary
Figure 21) and apoptosis of A549 human non-small cell lung
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FIGURE 5 | Luminescence is proportional to caspase activity and N-Z- DEVD-aLuc concentration. (A) Recombinant human caspase-3 (227 mU to 22.7 µU) and
N-Z-DEVD-aLuc (100 to 1µM) were titrated and assayed for 45min. (B) The effect of the pan-caspase inhibitor Z-VAD-fmk was tested in equimolar ratio of
N-Z-DEVD-aLuc at 10µM with 2.27 mU/reaction caspase-3. (C) Caspase-3 and -7 activation induced by the curcumin analog C150 (5–1.25µM) on A549 cells was
detected by N-Z-DEVD-aLuc, control corresponds to untreated sample. The results are shown as arithmetic mean values of three samples ± SEM. Anyhow, SEM
values are too small to be visible on the logarithmic scale of Figure 5A. ***p < 0.001.
carcinoma cells (Nagy et al., 2015; Hackler et al., 2016) and we
could detect the activation of caspase-3 by N-Z-DEVD-aLuc via
bioluminescence (Figure 5C).
To measure apoptosis directly in animals, an optical
imaging experiment was performed in vivo, administrating N-
Z-DEVD-aLuc to SCID mice (previously inoculated with the
stably expressing luciferase cell line U87-Luc) that had been
treated with chemotherapeutics previously. We used Ac-915,
a lipid droplet binding thalidomide analog inducing caspase-3
activation (Supplementary Figure 22) and oxidative stress and
apoptosis in different cancer cells (Nagy et al., 2013). Ac-915
enhanced the bioluminescent signal already at 6 h. Significantly
fewer signals were detected from control mouse having no
Ac-915 treatment, but injected with only N-Z-DEVD-aLuc
substrate, which represents the basal level of apoptosis. However,
the limitation of the widespread applicability of the luciferin
conjugated peptides in vivo is that luciferase enzyme activity
is indispensable, therefore luciferase transgenic mouse or cells
should be used in these studies.
CONCLUSION
A general strategy for the synthesis of N-peptide-6-amino-D-
luciferin conjugates has been developed. The strategy is based on
a newly established sequence of different transformations:
nitration → reduction → chlorine-cyanide exchange →
attachment of the C-terminal amino acid of the target sequence
(variable, depending on the protease to bemeasured)→ cysteine
FIGURE 6 | In vivo test of N-Z-DEVD-aLuc. N-Z-DEVD-aLuc (100 mg/kg, i.p.)
was administered to all SCID mice previously inoculated with U87-Luc
glioblastoma cells (middle). Apoptosis was induced by Ac-915 in all mice
except negative controls administered by PBS (left). Aminoluciferin was used
as positive control (right).
addition → attachment to resin → solid-phase peptide
synthesis (variable, depending on the protease to be measured)
→ cleavage from resin.
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The cornerstone of N-peptide-6-amino-D-luciferin conjugate
synthesis is the availability of 6-amino-2-cyanobenzothiazole in
large quantities. Although the used transformations (nitration,
NO2 reduction and cyanidation) are well-known in the literature,
our combination of these transformations, the equipment and
the solvents make it possible to prepare this material in larger
quantities than the published strategies; the key of the method
is the chlorine-cyano group exchange, the success of which
depends on the solvent. Using this larger quantity of 6-amino-
2-cyanobenzothiazole, we preparedN-Z-DEVD-aLuc with Fmoc
solid phase peptide synthesis. The material has already been
successfully used in in vivo optical imaging experiments.
The fact that in step 4 and 7 any amino acid can be used
means that our method provides a practical and scalable way for
preparation of other N-peptide-6-amino-D-luciferin conjugates
as well, which compounds have a crucial role in the development
of plate based, high-throughput viability assays.
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